Circulating MicroRNAs Associated with Liver Fibrosis in Chronic Hepatitis C Patients

Overview

Journal Biochem Biophys Rep

Specialty Biochemistry

Date 2020 Oct 5

PMID 33015376

Citations 16

Authors

B C A Cabral

L Hoffmann

T Bottaro

P F Costa

A L A Ramos

H S M Coelho

C A Villela-Nogueira

T P Urmenyi

D S Faffe

R Silva

Affiliations

Soon will be listed here.

Abstract

A major challenge in hepatitis C research is the detection of early potential for progressive liver disease. MicroRNAs (miRNAs) are small RNAs that regulate gene expression and can be biomarkers of pathological processes. In this study, we compared circulating miRNAs identified in hepatitis C virus (HCV)-infected patients presenting two extremes of liver disease: mild/moderate fibrosis and cirrhosis. The patients in the cirrhosis group subsequently developed hepatocellular carcinoma (HCC). We identified 163 mature miRNAs in the mild/moderate fibrosis group and 171 in the cirrhosis group, with 144 in common to both groups. Differential expression analysis revealed 5 upregulated miRNAs and 2 downregulated miRNAs in the cirrhosis group relative to the mild/moderate fibrosis group. Functional analyses of regulatory networks (target gene and miRNA) identified gene categories involved in cell cycle biological processes and metabolic pathways related to cell cycle, cancer, and apoptosis. These results suggest that the differentially expressed circulating miRNAs observed in this work (miR-215-5p, miR-483-5p, miR-193b-3p, miR-34a-5p, miR-885-5p, miR-26b-5p and miR -197-3p) may be candidates for biomarkers in the prognosis of liver disease.

Citing Articles

miRNAs and Hematological Markers in Non-Alcoholic Fatty Liver Disease-A New Diagnostic Path?.

Michalak A, Guz M, Kozicka J, Cybulski M, Jeleniewicz W, Telejko I Biomedicines. 2025; 13(1).

PMID: 39857813 PMC: 11762403. DOI: 10.3390/biomedicines13010230.

Extracellular Vesicles in Viral Liver Diseases.

Kouroumalis E, Tsomidis I, Voumvouraki A Viruses. 2024; 16(11).

PMID: 39599900 PMC: 11598962. DOI: 10.3390/v16111785.

Characterization of the SARS-CoV-2 Genome 3'-Untranslated Region Interactions with Host MicroRNAs.

Frye C, Cunningham C, Mihailescu M ACS Omega. 2024; 9(34):36148-36164.

PMID: 39220490 PMC: 11360049. DOI: 10.1021/acsomega.4c01050.

Oncoviral Infections and Small Extracellular Vesicles.

Wazny L, Whiteside T, Pietrowska M Viruses. 2024; 16(8).

PMID: 39205265 PMC: 11359865. DOI: 10.3390/v16081291.

The Role of Epigenetic Mechanisms in the Pathogenesis of Hepatitis C Infection.

Zychowska J, Cmil M, Skorka P, Olejnik-Wojciechowska J, Plewa P, Bakinowska E Biomolecules. 2024; 14(8).

PMID: 39199374 PMC: 11352264. DOI: 10.3390/biom14080986.

References

Roy S, Benz F, Cardenas D, Vucur M, Gautheron J, Schneider A . miR-30c and miR-193 are a part of the TGF-β-dependent regulatory network controlling extracellular matrix genes in liver fibrosis. J Dig Dis. 2015; 16(9):513-24. DOI: 10.1111/1751-2980.12266. View

Castera L, Hezode C, Roudot-Thoraval F, Bastie A, Zafrani E, Pawlotsky J . Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut. 2003; 52(2):288-92. PMC: 1774979. DOI: 10.1136/gut.52.2.288. View

Huan L, Liang L, He X . Role of microRNAs in inflammation-associated liver cancer. Cancer Biol Med. 2017; 13(4):407-425. PMC: 5250599. DOI: 10.20892/j.issn.2095-3941.2016.0071. View

Ishida H, Tatsumi T, Hosui A, Nawa T, Kodama T, Shimizu S . Alterations in microRNA expression profile in HCV-infected hepatoma cells: involvement of miR-491 in regulation of HCV replication via the PI3 kinase/Akt pathway. Biochem Biophys Res Commun. 2011; 412(1):92-7. DOI: 10.1016/j.bbrc.2011.07.049. View

Robinson M, McCarthy D, Smyth G . edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2009; 26(1):139-40. PMC: 2796818. DOI: 10.1093/bioinformatics/btp616. View

Zhang Z, Meng H, Wang N, Liang L, Liu L, Lu S . Serum microRNA 143 and microRNA 215 as potential biomarkers for the diagnosis of chronic hepatitis and hepatocellular carcinoma. Diagn Pathol. 2014; 9:135. PMC: 4226970. DOI: 10.1186/1746-1596-9-135. View

Xu C, Liu S, Fu H, Li S, Tie Y, Zhu J . MicroRNA-193b regulates proliferation, migration and invasion in human hepatocellular carcinoma cells. Eur J Cancer. 2010; 46(15):2828-36. DOI: 10.1016/j.ejca.2010.06.127. View

Gui J, Tian Y, Wen X, Zhang W, Zhang P, Gao J . Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin Sci (Lond). 2010; 120(5):183-93. PMC: 2990200. DOI: 10.1042/CS20100297. View

Shwetha S, Gouthamchandra K, Chandra M, Ravishankar B, Khaja M, Das S . Circulating miRNA profile in HCV infected serum: novel insight into pathogenesis. Sci Rep. 2013; 3:1555. PMC: 3615409. DOI: 10.1038/srep01555. View

10.

Van Keuren-Jensen K, Malenica I, Courtright A, Ghaffari L, Starr A, Metpally R . microRNA changes in liver tissue associated with fibrosis progression in patients with hepatitis C. Liver Int. 2015; 36(3):334-43. PMC: 5049661. DOI: 10.1111/liv.12919. View

11.

Huang S, He X . The role of microRNAs in liver cancer progression. Br J Cancer. 2010; 104(2):235-40. PMC: 3031886. DOI: 10.1038/sj.bjc.6606010. View

12.

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

13.

Schwarzenbach H, Nishida N, Calin G, Pantel K . Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol. 2014; 11(3):145-56. DOI: 10.1038/nrclinonc.2014.5. View

14.

Friedman R, Farh K, Burge C, Bartel D . Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2008; 19(1):92-105. PMC: 2612969. DOI: 10.1101/gr.082701.108. View

15.

Roderburg C, Luedde T . Circulating microRNAs as markers of liver inflammation, fibrosis and cancer. J Hepatol. 2014; 61(6):1434-7. DOI: 10.1016/j.jhep.2014.07.017. View

16.

. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018; 69(2):461-511. DOI: 10.1016/j.jhep.2018.03.026. View

17.

Reid G, Kirschner M, van Zandwijk N . Circulating microRNAs: Association with disease and potential use as biomarkers. Crit Rev Oncol Hematol. 2010; 80(2):193-208. DOI: 10.1016/j.critrevonc.2010.11.004. View

18.

Cermelli S, Ruggieri A, Marrero J, Ioannou G, Beretta L . Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One. 2011; 6(8):e23937. PMC: 3160337. DOI: 10.1371/journal.pone.0023937. View

19.

Ellis E, Mann D . Clinical evidence for the regression of liver fibrosis. J Hepatol. 2012; 56(5):1171-1180. DOI: 10.1016/j.jhep.2011.09.024. View

20.

Wei W, Tang H, Tang L . MicroRNA-34a inhibits metastasis in liver cancer cells. Oncol Lett. 2018; 16(6):6960-6965. PMC: 6256319. DOI: 10.3892/ol.2018.9555. View